NCT00508924View on ClinicalTrials.gov

Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)

PHASE2CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

August 31, 2005

Study Completion Date

October 31, 2006

Conditions
Coronary Artery DiseaseAngina, Unstable
Interventions
DRUG

Argatroban

DRUG

Argatroban

DRUG

Argatroban

DRUG

Heparin

Trial Locations (8)

Unknown

Aalst

Bad Nauheim

Cologne

Dachau

Düren

Frankfurt

Halle

Mainz

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY